CXCR5/CD185 recombinant proteins and antibodies

C-X-C Chemokine Receptor Type 5 (CXCR5), also known as CD185, BLR1 or MDR15, is a chemokine receptor predominantly expressed on B cells, T cells, and dendritic cells. CXCR5 regulates the migration and positioning of immune cells in lymphoid tissues by binding to its ligand CXCL13. This receptor plays a crucial role in immune responses, particularly in the activation and localization of B cells in lymph nodes and spleen. In addition to immune response, CXCR5 is essential in immune tolerance, lymphoid tissue formation, and the production of antibodies.

CXCR5 is implicated in the pathogenesis of various diseases, especially in immune-mediated disorders and cancer immunotherapy. Studies have shown that CXCR5 regulates the accumulation of B cells in lymph nodes, influencing the tumor immune microenvironment and thereby affecting anti-tumor immune responses. In certain cancers, including lymphomas, breast cancer, and lung cancer, CXCR5 expression is elevated, suggesting its role in immune evasion, tumor growth, and metastasis. Therefore, CXCR5 has become a potential target for therapy, particularly in the treatment of lymphomas, breast cancer, lung cancer, and other tumors.

Currently, drug development targeting CXCR5 focuses on small molecule inhibitors and monoclonal antibodies. These small molecule inhibitors aim to block the binding of CXCR5 to CXCL13, reducing immune cell migration and activation, thus interfering with the tumor microenvironment or alleviating symptoms of autoimmune diseases. Additionally, anti-CXCR5 monoclonal antibodies are under development, designed to specifically bind to CXCR5 and suppress its role in immune responses. As the understanding of CXCR5’s role in immune responses deepens, CXCR5-targeted drugs are expected to become important tools for treating lymphomas, lung cancer, breast cancer, and various immune diseases.

To assist in the development of CXCR5 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for CXCR5 targets. Products include active CXCR5 recombinant proteins, full-length CXCR5 proteins, CXCR5 reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of CXCR5 biotherapy, DIMA BIOTECH has also prepared a CXCR5 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CXCR5 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.